Changes in Prolactin and Insulin Resistance in PCOS Patients Undergoing Metformin Treatment: A Retrospective Study
Journal of Clinical Medicine · 20.12.2024 · 13 (24) · 7781
DOI: 10.3390/jcm13247781 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 20.12.2024. Verfasst von Tal Goldstein und 6 weiteren Autor:innen. Beteiligte Einrichtung: Klinik Favoriten, 1100 Vienna, Austria. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Prolactin levels have been shown to influence metabolic outcomes, including insulin resistance. Metformin is known to be beneficial in polycystic ovary syndrome (PCOS) patients. PCOS women might react differently to metformin treatment depending on their baseline prolactin levels.
Methods
In this retrospective study, the homeostasis model assessment for insulin resistance (HOMA-IR), prolactin, luteinizing hormone (LH), follicle-stimulating hormone (FSH), the LH:FSH ratio, and total testosterone and sex hormone-binding globulin (SHBG) were measured in 75 obese/overweight women with PCOS and insulin resistance before initiation of metformin treatment and after 6–8 months.
Results
At baseline, HOMA-IR was inversely correlated to SHBG (r = −0.408; p < 0.001) and prolactin (r = −0.402; p < 0.001). After 6–8 months of metformin treatment, the LH:FSH ratio and the HOMA-IR declined significantly (p < 0.05). A significant positive correlation could be shown between basal prolactin and the difference in the HOMA-IR (r = 0.233; p = 0.044). Women with lower baseline prolactin (≤14.9 ng/mL) revealed a sharper decline in HOMA-IR (−0.8, IQR −1.0; −0.5 vs. −0.6, IQR −0.8; −0.3; p = 0.049) as well as an increase in prolactin at follow-up (1.6 ng/mL, IQR −0.2;3.8 vs. −1.3, IQR −4.6;3.2; p = 0.003) compared to patients with a baseline prolactin > 14.9 ng/mL.
Conclusions
In overweight/obese, insulin-resistant PCOS women, lower baseline prolactin levels are associated with higher baseline HOMA-IR levels as well as with a better response to metformin treatment. More data are necessary to prove these observations in larger populations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Klinik Favoriten, 1100 Vienna, Austria.
- Clinical Division of Gynecological Endocrinology and Reproductive Medicine, Department of Obstetrics and Gynecology, Medical University of Vienna, 1090 Vienna, Austria.
- Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, 40-055 Katowice, Poland.
- Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria.
ORCID-Profile: Johannes Ott, Robert Krysiak, Rodrig Marculescu, Marlene Hager
Zitieren
APA
Goldstein, T., Ott, J., Katzensteiner, P., Krysiak, R., Marculescu, R., Boegl, M., & Hager, M. (2024). Changes in Prolactin and Insulin Resistance in PCOS Patients Undergoing Metformin Treatment: A Retrospective Study. Journal of Clinical Medicine, 13(24), 7781. https://doi.org/10.3390/jcm13247781
Vancouver
Goldstein T, Ott J, Katzensteiner P, Krysiak R, Marculescu R, Boegl M, et al. Changes in Prolactin and Insulin Resistance in PCOS Patients Undergoing Metformin Treatment: A Retrospective Study. Journal of Clinical Medicine. 2024;13(24):7781. doi:10.3390/jcm13247781
BibTeX
@article{Goldstein2024,
author = {Goldstein, Tal and Ott, Johannes and Katzensteiner, Paula and Krysiak, Robert and Marculescu, Rodrig and Boegl, Magdalena and Hager, Marlene},
title = {Changes in Prolactin and Insulin Resistance in PCOS Patients Undergoing Metformin Treatment: A Retrospective Study},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {24},
pages = {7781},
doi = {10.3390/jcm13247781}
}
EUVIMED